Navigation Links
NIH doubles support for vital HIV/AIDS research center
Date:11/1/2007

The National Institutes of Health will award $15 million over the next five years to the Center for AIDS Research of the University of California, San Francisco and the Gladstone Institute for Virology and Immunology to continue its pioneering translational researcha doubling of its previous five-year award.

The UCSF-GIVI Center for AIDS Research is absolutely crucial to maintaining and extending the leadership role of San Francisco in responding to the HIV epidemic. It brings together a true community of HIV investigators who represent the many disciplines and campus sites involved in this effort, said Paul Volberding, MD, the centers co-director and professor and vice-chair, UCSF Department of Medicine and Chief of the Medical Service at the San Francisco Veterans Affairs Medical Center.

Co-directed by Warner Greene, MD, PhD, director of the UCSF affiliated GIVI, the Center for AIDS Research provides strategic, educational and scientific services to HIV/AIDS researchers. Its research goal is to expand the intersections of basic, clinical and behavioral/epidemiological HIV research. It provides infrastructure support to over $80 million of funded HIV/AIDS research at UCSF and affiliated institutions.

CFAR is particularly vital in encouraging the collaborations across conventional scientific disciplines that can direct the amazing expertise of UCSF scientists to address the newest challenges of HIV disease. As we address scientific and clinical challenges here in San Francisco as well as in the world-wide epidemic, CFAR will provide the essential infrastructure to facilitate the most important and innovative science we all depend on, said Greene.

The NIH CFAR program, first funded in 1988, currently supports 19 centers based at leading HIV/AIDS research institutions. UCSF was one of the first institutions to be funded under this program. In 2003, the program was modified to provide greater funding to larger institutions.

The growt
'/>"/>

Contact: Jeff Sheehy
jsheehy@ari.ucsf.edu
415-597-8165
University of California - San Francisco
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Breast cancer risk doubles by high sex hormone levels
2. Down syndrome life anticipation doubles
3. Depression doubles mortality risk after CABG
4. China Doubles Its Investment In AIDS/HIV Treatment.
5. Colon Cancer Death Rate Doubles As Patients Stop Chemotherapy
6. High Carb Diet Doubles Fat Loss
7. Sleep Apnea Doubles Stroke Risk In Elderly
8. Brains pleasure chemical doubles up for pain as well
9. Sight loss risk doubles in overweight people
10. Stroke Risk Nearly Doubles for Siblings of People Who Have Had a Stroke
11. Snacking While Driving Doubles Accident Rates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2008)...esults of a 10-year study published in the August ...found that magnesium sulfate administered to women...he risk of cerebral palsy by 50 percent. The Benef...) trial was conducted in 18 centers in the U.S., i...renatal intervention ever found to reduce the inst...
(Date:8/29/2008)... http://www.aronowitzmd.com [Los An...espected experience in plastic surgery procedures ...consideration may be necessary for these patients,...e an established specialty of procedures for after...es, CA (PRWEB) August 29, 2008 -- Bariatric surger...
(Date:8/28/2008)...ues increase 138% versus Q2 2007 - Nine new Cen...RNewswire-FirstCall/ - CRH Medical Corporation,(CR... three and six months,ended June 30, 2008 (all fig...ths ended June 30, 2008 increased 138% to $1,653,8...7. Revenue for the six months ended June,30, 2008 ...
(Date:8/28/2008)...ion will be based in the Northeast region with mor...xt year, HARRISBURG, Pa., Aug. 28 /PRNewswire-USN...ity has hired a Patient Safety Liaison for the,Nor...eport to the,Pennsylvania Patient Safety Reporting...ylvania citizens., "Last year in focus groups wit...
Breaking Medicine News(10 mins):Health News:National study shows magensium sulfate reduces risk of cerebral palsy in premature births 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 2Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 3Health News:Dr. Joel Aronowitz, Specialist in Los Angeles Body Lift, Announces Plastic Surgery Options After Bariatric Surgery Weight Loss 4Health News:CRH Medical reports Q2 2008 results 2Health News:CRH Medical reports Q2 2008 results 3Health News:CRH Medical reports Q2 2008 results 4Health News:CRH Medical reports Q2 2008 results 5Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 2Health News:Pennsylvania Patient Safety Authority Hires Patient Safety Liaison to Help Healthcare Facilities Implement Guidance 3
...ngland register the lowest number of early deaths ...ls of obesity and the longest life expectancy. By...s the lowest life expectancy for men. Near neighbo...men. Those in both cities live, on average, near...
...ng the link between levels of urate in the blood a...the Harvard School of Public Health (HSPH) have fo...ted with a reduced risk of the disease. Urate is...ugh high levels can lead to gout, urate might also...
...er for three years. Circuit Judge Weber McCraw, wh...r the option of serving some of her sentence in a...nnessee preacher told the Jurors presiding over he... shot her husband. She had been suffering domestic...
...patients who have recently suffered a major heart ...rom their own bone marrow during routine coronary...her the stem cells will repair heart muscle cells ...ing late scar formation and hence impaired heart c...
Other Medicine News:Health News:Southern England Far Healthier Than the North 2Health News:Urate Reduces the Risk of Parkinsons Disease 2Health News:Domestic Abuse Led Wife Killing Her Preacher Husband 2Health News:A New Milestone in Stem Cell Research 2
(Date:8/27/2008)...tients in the VELCADE, melphalan and prednisone ar... well as a 30 percent complete response -, CAMBRI...e Takeda,Oncology Company today announced the publ...d, Phase III VISTA(1) trial in this week,s edition...ts showed a significant survival,benefit and a 30 ...
(Date:8/27/2008)...First Phase 3 data, from BLISS-52 trial, expected ...LISS-76, expected by fall 2009 -, ROCKVILLE, Md.,...iences, Inc. (Nasdaq: HGSI ) today announced it h...S-76, the second of two pivotal Phase 3,randomized... patients with,active systemic lupus erythematosus...
(Date:8/26/2008)...IANAPOLIS, Aug. 26 /- Semafore Pharma...national Congress on Targeted Therapies,in Cancer ...ovel,multi-targeted kinase inhibitors that demonst...l studies., A novel and proprietary molecular sca...ing allowing for the design of pan-PI3 kinase inhi...
(Date:8/26/2008)...LO PARK, Calif., Aug. 26 /-... the positive one-year follow-up data,from the CUS...e of the,peer-reviewed journal, EuroIntervention. ...tella, M.D., of University Medical Center Utrecht,...II Investigators from 13 clinical,sites across Eur...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 2Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 3Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 4Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 5Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial 6Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 2Semafore Broadens Pipeline With Multi-Targeted Kinase Inhibitors 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 2XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 3XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention 4Blood pressure drug telmisartan shows powerful activity against stroke 1570 1Blood pressure drug telmisartan shows powerful activity against stroke 1570 2Blood pressure drug telmisartan shows powerful activity against stroke 1570 3Ireland Cancer Center researchers advance stem cell gene therapy 1565 1Ireland Cancer Center researchers advance stem cell gene therapy 1565 2Ireland Cancer Center researchers advance stem cell gene therapy 1565 3Wind power explored off Californias coast 1563 1Wind power explored off Californias coast 1563 2Wind power explored off Californias coast 1563 3Wind power explored off Californias coast 1563 4Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 1Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 2Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 3Ceregene Presents Long term Follow up From Phase 1 Trial of CERE 120 in Parkinsons Disease 1050 4
The PachPen uses state-of-the-art waveform analysis and a probe that samples at a 65MHz rate to obtain precise readings. The PachPen stores and averages nine measurements and calculates IOP correctio
...ailable as both regular and filter tips. Sterilize...re efficient sterilization and are delivered with ...e of irradiation. Sterilized Diamond Tips are read...k Diamond Tips are wrapped in medical device quali...
300 L, Bulk Recommended for 250 and 300 L pipettes.
Ambion's barrier tips prevent cross-contamination of samples by means of an aerosol filter. They are RNase- and DNase-free and are ideal for handling RNA, PCR applications, and for working with radio
Medicine Products: